John Randall Eckardt
102 works · 3,734 citations · h-index 33
Top works
- Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer.
- Phase I and pharmacokinetic trial of weekly CPT-11.
- Phase I clinical trial of taxotere administered as either a 2-hour or 6-hour intravenous infusion.
- Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer
- Initial phase I evaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation.
- Irinotecan Plus Gemcitabine Induces Both Radiographic and CA 19-9 Tumor Marker Responses in Patients With Previously Untreated Advanced Pancreatic Cancer
- Phase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapy.
- Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies
- Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.
- Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors
- Open-Label, Multicenter, Randomized, Phase III Study Comparing Oral Topotecan/Cisplatin Versus Etoposide/Cisplatin As Treatment for Chemotherapy-Naive Patients With Extensive-Disease Small-Cell Lung Cancer
- Heat shock proteins and drug resistance
- Phase I trial of paclitaxel and gemcitabine administered every two weeks in patients with refractory solid tumors
- A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
- Phase I and pharmacologic study of oral topotecan administered twice daily for 21 days to adult patients with solid tumors.
- Comparison of engraftment and acute GVHD in patients undergoing cryopreserved or fresh allogeneic BMT.
- A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea
- A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin)
- Phase I and pharmacokinetic studies of topotecan administered as a 72 or 120 h continuous infusion
- 927 A phase I and bioavailability study of oral topotecan